Physician profile
John E Wang
NPI 1518429869
$2,550.40
in general payments reported to CMS, 2019-2025
13 companies · $1,797 in 2025
The $1,797 reported for 2025 was more than what 76% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $753 · 2025: $1,797.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,550.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,550.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $781.34 | 2024-2025 | |
| 3-D Matrix, INC. | $644.83 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $406.61 | 2024-2025 | Xifaxan |
| Boston Scientific Corporation | $227.01 | 2025 | General - Therapies, Accolade Sr |
| Mallinckrodt Hospital Products INC. | $123.20 | 2024 | Terlivaz |
| Lilly USA, LLC | $106.60 | 2025 | Omvoh |
| Janssen Biotech, INC. | $79.88 | 2025 | Tremfya |
| Qol Medical, LLC | $53.57 | 2025 | Sucraid |
| Regeneron Healthcare Solutions, INC. | $37.81 | 2025 | Dupixent |
| Celltrion USA INC. | $28.50 | 2025 | Vegzelma |
| Braintree Laboratories, INC. | $25.05 | 2025 | Suflave, Sutab |
| Gilead Sciences, INC. | $20.53 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.47 | 2025 | Entyvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.